ARUP Launches First Clinical Spectral Flow Cytometry Assay for MRD Assessment in Multiple Myeloma
SALT LAKE CITY, July 20, 2026 /PRNewswire/ -- ARUP Laboratories today announced the launch of ARUP CLARISPECT™ Multiple Myeloma MRD by Spectral Flow Cytometry. The new assay will characterize small neoplastic populations with greater confidence and sensitivity than conventional flow...
View original →